Annexon (NASDAQ:ANNX) used its Investor Day presentation to outline the scientific rationale and clinical progress for ...

Even in an era of remarkable therapeutics for neovascular age-related macular degeneration, there remains a lack of therapies to improve vision in dry AMD. Many patients continue to live with central ...

Light therapy with multiple wavelengths may safely improve vision, reduce new retinal damage, and improve vision related quality of life in patients with dry age related macular degeneration.

Annexon, Inc. reports complete enrollment in the ARCHER II trial for vonaprument, targeting dry AMD with topline data due 2026. Annexon, Inc. announced the successful completion of enrollment for its ...

Read this issue’s cover story titled “Specialists navigate changing, challenging landscape of geographic atrophy management.” More knowledge about the diagnosis and manageme ...

The evidence evaluating the effect of cataract surgery on the chances people with dry age-related macular degeneration (AMD) will convert to the more severe wet form of the condition has been uneven ...

At least 20 million Americans ages 40 and older have age-related macular degeneration, and the threat posed by the vision-robbing condition will only grow larger as the population ages. Despite the ...

Around a third of people over the age of 80 suffer from age-related macular degeneration (AMD), with an estimated 20 million Americans aged 40 and older currently living with AMD. Most cases are the ...

Julie Rosenthal, MD, MS, discusses signs and symptoms of age-related macular degeneration as well as methods of treatment. Rosenthal: Some people don't have any symptoms at all when the disease is ...